Literature DB >> 1320097

Detection of multiple Epstein-Barr viral strains in allogeneic bone marrow transplant recipients.

J W Gratama1, E T Lennette, B Lönnqvist, M A Oosterveer, G Klein, O Ringdén, I Ernberg.   

Abstract

We have previously shown in 3 allogeneic bone-marrow transplant (BMT) recipients that complete replacement of recipient marrow was associated with the elimination of the pretransplant Epstein-Barr virus (EBV) strain of the recipient. To study the kinetics of EBV elimination and reinfection in more detail, we have performed a longitudinal study of BMT recipients combining serology, virus isolation from mouthwashes and peripheral blood, and EBV strain characterization. Oropharyngeal EBV excretion was found to persist after the cytoreductive therapy prior to BMT, whereas EBV-carrying cells in the blood were detected only after 5 weeks following BMT. During the first month post-BMT, 2 different EBV strains could be isolated from sequential mouth-washes of 3 patients. The initial strains were found to persist up to 7, 21, and 29 days post-BMT, whereas the subsequent strains appeared at 21, 42, and 34 days post-BMT, respectively. Thus, the original EBV strain may persist only for a limited time after BMT, and the oropharyngeal epithelium may be reinfected by a new EBV strain from the blood within 3 weeks. With respect to the coexistence of multiple EBV strains, 2 patterns were evident. From the day 62 mouthwash of 1 patient, 1 Type A and 1 Type B strain were isolated. From the day 180 mouthwash of a second patient, a dominant Type A strain was recovered, together with 6 "variant" strains that differed from each other by only a single EBNA protein (EBNA 1). This pattern may be explained by viral recombinations during replication, which may form the basis for the vast polymorphism of EBV observed in unrelated individuals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1320097     DOI: 10.1002/jmv.1890370107

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

1.  Epstein-Barr virus infection in allogeneic marrow grafting: lessons for transplant physicians and virologists.

Authors:  J W Gratama; M A Oosterveer; J Lepoutre; W E Fibbe; O Ringdén; J M Vossen; R Willemze; R L Bolhuis; J J van Rood; I Ernberg
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

2.  Epstein-Barr virus infection after unrelated cord blood transplantation: reactivation or reinfection?

Authors:  Keisei Kawa; Akihisa Sawada; Maho Koyama; Masami Inoue
Journal:  Int J Hematol       Date:  2007-04       Impact factor: 2.490

3.  Epidemiology of infection with Epstein-Barr virus types 1 and 2: lessons from the study of a T-cell-immunocompromised hemophilic cohort.

Authors:  Q Y Yao; D S Croom-Carter; R J Tierney; G Habeshaw; J T Wilde; F G Hill; C Conlon; A B Rickinson
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Isolation of intertypic recombinants of Epstein-Barr virus from T-cell-immunocompromised individuals.

Authors:  Q Y Yao; R J Tierney; D Croom-Carter; G M Cooper; C J Ellis; M Rowe; A B Rickinson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

5.  Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals.

Authors:  Q Y Yao; R J Tierney; D Croom-Carter; D Dukers; G M Cooper; C J Ellis; M Rowe; A B Rickinson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

6.  Intensification of GVHD prophylaxis interferes with the effects of pretransplant herpes virus serology on the occurrence of grades II-IV acute graft-versus-host disease.

Authors:  J W Gratama; H vd Nat; H T Weiland; T Stijnen; W E Fibbe; J M Vossen; R Willemze; L F Verdonck
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

Review 7.  Viral infections in severely immunocompromised cancer patients.

Authors:  S M Devine; J R Wingard
Journal:  Support Care Cancer       Date:  1994-11       Impact factor: 3.603

8.  Development of a recombinant enzyme-linked immunosorbent assay for detection of antibodies against Epstein-Barr virus nuclear antigens 2A and 2B.

Authors:  R Geertsen; A Espander-Jansson; M Dobec; P Price; W Wunderli; L Rymo
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

9.  Mature B cells are required for acute splenic infection, but not for establishment of latency, by murine gammaherpesvirus 68.

Authors:  K E Weck; M L Barkon; L I Yoo; S H Speck; I V Virgin HW
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

Review 10.  The antiviral prophylaxis of post-transplant lymphoproliferative disorder.

Authors:  C L Davis
Journal:  Springer Semin Immunopathol       Date:  1998
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.